Bailard Inc. boosted its position in  Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 123.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 37,704 shares of the medical equipment provider’s stock after acquiring an additional 20,817 shares during the period. Bailard Inc.’s holdings in Hologic were worth $2,821,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of HOLX. Romano Brothers AND Company bought a new stake in shares of  Hologic in the fourth quarter worth about $25,000.  Whittier Trust Co. increased its stake in shares of  Hologic by 90.0% during the fourth quarter. Whittier Trust Co. now owns 380 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 180 shares during the period.  Salem Investment Counselors Inc. increased its stake in shares of  Hologic by 163.9% during the second quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 341 shares during the period.  Lansing Street Advisors bought a new position in shares of  Hologic during the third quarter valued at approximately $44,000.  Finally, Toth Financial Advisory Corp purchased a new stake in  Hologic in the fourth quarter worth $45,000. Hedge funds and other institutional investors own  95.17% of the company’s stock.

Shares of NASDAQ:HOLX opened at $82.51 on Wednesday. The company has a market capitalization of $20.34 billion, a PE ratio of 21.05, a PEG ratio of 1.48 and a beta of 1.00. The business has a fifty day moving average price of $80.89 and a 200-day moving average price of $76.48. Hologic, Inc. has a 1-year low of $59.78 and a 1-year high of $86.65. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.21 and a quick ratio of 3.50.

Hologic (NASDAQ:HOLX – Get Rating) last released its quarterly earnings data on Wednesday, February 1st. The medical equipment provider reported $1.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.17. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 22.17% and a return on equity of 25.12%. Hologic’s revenue was down 27.0% compared to the same quarter last year. During the same period last year, the business earned $2.17 EPS.  As a group, equities analysts expect that  Hologic, Inc. will post 3.74 EPS for the current fiscal year.

In other Hologic news, insider Benjamin Jordan Cohn sold 9,128 shares of the stock in a transaction on Tuesday, February 7th. The stock was sold at an average price of $85.28, for a total transaction of $778,435.84. Following the sale, the insider now directly owns 14,298 shares in the company, valued at approximately $1,219,333.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.66% of the stock is owned by company insiders.

HOLX has been the topic of a number of research analyst reports. Wells Fargo & Company boosted their price objective on shares of Hologic from $75.00 to $80.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 10th. Morgan Stanley boosted their price target on shares of Hologic from $74.00 to $81.00 and gave the company an “equal weight” rating in a research report on Friday, February 3rd. Cowen raised their price objective on shares of Hologic from $86.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, February 2nd. Citigroup upped their target price on Hologic from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Thursday, February 2nd. Finally, SVB Leerink raised their target price on Hologic from $90.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 2nd. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.23.

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Get Rating).

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.